Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Adobe Systems Inc (ADBE) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

Adobe Systems IncTrade
Inovio Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Adobe Systems Inc vs Inovio Pharmaceuticals Inc — how do they compare? Adobe Systems Inc trades at $255.98 (market cap $104.82B), while Inovio Pharmaceuticals Inc trades at $0.75 (market cap $78.55M). The key difference: Adobe Systems Inc is far larger — about 1334.4× Inovio Pharmaceuticals Inc's market cap, and Adobe Systems Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

ADBEINO
Market Cap
$104.82B$78.55M
Volume
5,187,646
Sector
TechnologyHealth
52-Week High
$367.46$2.87
52-Week Low
$193.41$0.66
Enterprise Value
$106.26B$49.56M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Adobe Systems Inc

Adobe (ADBE) trades at $272.96, up 2.92% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with 2025 revenue of $23.77B and net income of $7.13B, maintaining exceptional profitability margins. Recent earnings beats and accelerating revenue growth contrast with market concerns about AI competition and CEO transition.

Adobe presents a compelling value opportunity trading below analyst consensus targets despite strong operational performance. Key risks include AI disruption threats and ongoing leadership transition, while institutional accumulation and positive earnings momentum support potential upside. The stock's current valuation multiples appear attractive relative to growth prospects.

Inovio Pharmaceuticals Inc

INO shares trade at $0.74, up 10.24% today, but remain significantly below analyst consensus targets. The biotech firm shows improving operational trends with three consecutive quarterly earnings beats, though financials reveal substantial losses with -130% net margin. Technical indicators signal bearish momentum despite neutral oscillators. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with the company recently raising $20 million to fund operations.

Outlook hinges on FDA approval of INO-3107, representing a binary event that could drive substantial upside given the $3.25 consensus target. However, persistent cash burn, negative profitability metrics, and ongoing shareholder litigation pose significant risks. The stock offers high-risk, event-driven potential for speculative investors willing to accept regulatory and financial uncertainty.

Returns comparison

Trailing returns across standard periods

About Adobe Systems Inc

Adobe Inc. develops, markets, and supports computer software products and technologies. The Company's products allow users to express and use information across all print and electronic media. Adobe offers a line of application software products, type products, and content for creating, distributing, and managing information.

Read more on ADBE

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO